神經組織工程和細胞移植的現況和新興市場 是由出版商Medtech Insight在2010年08月所出版的。
這份英文市場調查報告書包含131 Pages 價格從美金4750起跳。
美國的神經組織工程和細胞移植市場預計在2019年會超過136億美金。
本報告書內容包括:主要的神經疾病概要、組織工程、細胞移植的趨勢、產品開發所加入的企業介紹、技術開發趨勢等彙整、內容綱要摘記如下:
實施摘要
第1章 神經系統和神經疾病的概要
- 神經系統
- 神經疾病及其他疾病
- 阿茲海默症
- 筋萎縮性側索硬化症
- 癲癇
- 多發性硬化症
- 帕金森氏症
- 腦中風
第2章 組織工程及組織重建技術
- 生技材料
- 人工生技材料
- 生物學性衍生技材料
- 混合生技材料
- 遺傳基因更換生技材料
- 支架
- 血管支架
- 細胞培養技術
- 幹細胞技術
- 免疫隔離技術
第3章 神經組織工程及細胞移植產品的現況和新興市場
- 遺傳基因療法
- 增殖因素
- 神經移植
- 縮氨酸
- 再髓鞘化單株抗體
- 幹細胞療法
- 視網膜色素上皮細胞移植
- 市場分析
- 競爭分析
第4章 企業介紹
- Acorda Therapeutics, Inc.
- AxoGen, Inc.
- Ceregene, Inc.
- Genzyme Corporation
- Geron Corporation
- Integra LifeSciences Corporation
- Isis Pharmaceuticals, Inc.
- Neuralstem, Inc.
- NeuroNova AB
- ReNeuron Group PLC
附錄：企業清冊
Abstract
This new report from Medtech Insight analyzes the market for tissue
engineering products for neurology indications. The potential United States
(U.S.) market for tissue engineering products for neurology applications is
substantial, with some segments representing multibillion-dollar
opportunities. In the U.S., the total potential market for these products is
expected to exceed $13.6 billion in the year 2019.
Market segments covered by this report include tissue engineering and cell
transplantation products for the treatment of neurologic diseases/disorders
including Alzheimer' s disease, epilepsy, Huntington' s disease, multiple
sclerosis, Parkinson' s disease, peripheral nerve regeneration, spinal cord
injury, and stroke. A variety of tissue engineering approaches show promise
for treating diseases and disorders of the central nervous system, and many
companies are developing product candidates for the U.S. market based on
several technologies including gene therapy, growth factors, monoclonal
antibodies, nerve grafting, and stem cells.
In addition, this report includes an overview of some of the most prevalent
neurologic disorders and diseases in the U.S. as well as an analysis of
emerging competitors and products/technologies that currently are under
development.
This Medtech Insight report is the third in a series of reports covering U.S.
tissue engineering markets. Upcoming reports in this series will provide
analyses of U.S. markets for tissue-engineered products for organ
regeneration, skin replacement, and urology applications.
Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary
and secondary research among the clinicians, researchers, and competitors in
the marketplace, and draw upon the industry expertise of a network of industry
insiders. Medtech Insight exhaustively corroborates the data as a baseline for
completing forward-looking analysis and providing insight into product,
technology and market evolution.
Report Statistics
- 131 Pages
- 19 Exhibits
- 10 Company Profiles
Table of Contents
EXECUTIVE SUMMARY
- i. The Nervous System
- ii. Neurologic and Other Diseases/Disorders
- a. Alzheimer' s Disease
- b. Amyotrophic Lateral Sclerosis
- c. Epilepsy
- d. Multiple Sclerosis
- e. Parkinson' s Diseases
- f. Stroke
- iii. Tissue Engineering Technologies
- a. Biomaterials
- b. Cell Culture Technology
- c. Stem Cell Technology
- d. Immunoisolation Technology
- iv. Current and Emerging Markets for Neurologic Tissue Engineering and
Cell Transplantation Products
- a. Gene Therapy
- b. Growth Factors
- c. Nerve Grafting
- d. Stem Cell-Based Therapies
- e. Other Tissue Engineering Technologies
- f. Market Analysis
- v. Methodology
- Exhibit ES-1: Tissue-Engineered Neurology Products, Potential Market
Forecast, 2009 and 2019
1. OVERVIEW OF THE NERVOUS SYSTEM AND SELECTED NEUROLOGIC DISEASES/DISORDERS
- 1.1 The Nervous System
- 1.1.1 Sacral Nerves
- 1.1.2 Vagus Nerves
- 1.1.3 Neurons
- 1.1.4 The Brain
- 1.1.5 The Spine
- 1.2 Neurologic and Other Diseases/Disorders
- 1.2.1 Alzheimer' s Disease
- 1.2.1.1 Etiology
- 1.2.1.2 Epidemiology
- 1.2.2 Amyotrophic Lateral Sclerosis
- 1.2.2.1 Etiology
- 1.2.2.2 Epidemiology
- 1.2.3 Epilepsy
- 1.2.3.1 Etiology
- 1.2.3.2 Epidemiology
- 1.2.4 Multiple Sclerosis
- 1.2.4.1 Etiology
- 1.2.4.2 Epidemiology
- 1.2.5 Parkinson' s Disease
- 1.2.5.1 Etiology
- 1.2.5.2 Epidemiology
- 1.2.6 Stroke
- 1.2.6.1 Etiology
- 1.2.6.2 Epidemiology
- Exhibit 1-1: United States Population, by Age Group, Selected Years,
2000-2050
- Exhibit 1-2: The Sacral Nervous System
- Exhibit 1-3: The Vagus Nerve
- Exhibit 1-4: Anatomy of the Brain
- Exhibit 1-5: Anatomy of a Spinal Segment
- Exhibit 1-6: Alzheimer' s Disease, Facts and Figures
- Exhibit 1-7: Amyotrophic Lateral Sclerosis, Facts and Figures
- Exhibit 1-8: Epilepsy, Facts and Figures
- Exhibit 1-9: Multiple Sclerosis, Facts and Figures
- Exhibit 1-10: Parkinson' s Disease, Facts and Figures
- Exhibit 1-11: Stroke, Facts and Figures
2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES
- 2.1 Biomaterials
- 2.1.1 Synthetic Biomaterials
- 2.1.2 Biologically Derived Biomaterials
- 2.1.2.1 Collagen
- 2.1.2.2 Xenogeneic Tissue
- 2.1.3 Hybrid Biomaterials
- 2.1.4 Genetically Engineered Biomaterials
- 2.1.4.1 Deoxyribonucleic Acid Transfection Vectors
- 2.1.4.2 Genetically Manipulated Cells
- 2.1.4.3 Three-Dimensional Polymer Technology
- 2.1.4.4 Transgenics
- 2.1.4.5 Fibroblasts
- 2.1.4.6 Immortalized Neural Stem Cells
- 2.1.4.7 Gene-Activated Matrices
- 2.1.5 Scaffolds
- 2.1.6 Vascular Grafts
- 2.2 Cell Culture Technology
- 2.2.1 Bioreactors
- 2.2.1.1 Flatbed Perfusion Systems
- 2.2.1.2 Hollow Fiber Bioreactor Systems
- 2.2.1.3 Cell Suspension Systems
- 2.2.1.4 Disposable Bioreactors
- 2.3 Stem Cell Technology
- 2.3.1 Cell Extraction and Expansion
- 2.3.2 Bioreactors
- 2.4 Immunoisolation Technology
- 2.4.1 Chimeric Immunity
- 2.4.2 Cell Encapsulation Technology
- Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue
Engineering
- Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering
- Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction,
Expansion, and Separation Products and Technologies
3. CURRENT AND EMERGING MARKETS FOR NEUROLOGIC TISSUE ENGINEERING AND CELL TRANSPLANTATION PRODUCTS
- 3.1 Gene Therapy
- 3.1.1 Ceregene
- 3.1.2 Genzyme
- 3.1.3 Isis Pharmaceuticals
- 3.2 Growth Factors
- 3.2.1 Acorda Therapeutics
- 3.2.2 Alseres Pharmaceuticals
- 3.2.3 NeuroNova in collaboration with Medtronic
- 3.2.4 The Parkinson Study Group
- 3.3 Nerve Grafting
- 3.3.1 AxoGen
- 3.3.2 Integra LifeSciences
- 3.4 Peptides
- 3.4.1 CellMed/Biocompatibles International
- 3.5 Remyelinating Monoclonal Antibodies
- 3.5.1 Acorda Therapeutics
- 3.6 Stem Cell-Based Therapies
- 3.6.1 Human Adult Stem Cells
- 3.6.1.1 BrainStorm Cell Therapeutics
- 3.6.1.2 NeuroNova
- 3.6.1.3 ReNeuron
- 3.6.2 Human Embryonic Stem Cells
- 3.6.3 Fetal Neural Stem Cells
- 3.6.3.1 Neuralstem
- 3.6.3.2 StemCells
- 3.6.4 Fetal Porcine Cells
- 3.6.5 Nasal Cavity-Derived Stem Cells
- 3.6.6 Skin-Derived Stem Cells
- 3.7 Retinal Pigmented Epithelial Cell Transplants
- 3.7.1 Titan Pharmaceuticals in collaboration with Bayer
- 3.8 Market Analysis
- 3.8.1 Market Drivers
- 3.8.2 Market Limiters
- 3.9 Competitive Analysis
- Exhibit 3-1: 2010, Selected Tissue-Engineered/Regeneration Products for
Neurology Applications
- Exhibit 3-2: Tissue-Engineered Neurology Products, Potential Market
Forecast, 2009 and 2019
- Exhibit 3-3: Technologies for Neurologic Tissue Engineering, by
Indication, 2009 and 2019
- Exhibit 3-4: Technologies for Tissue Engineering and Cell Transplantation,
Product Introduction Forecast, by Indication, 2014 and 2019
4. COMPANY PROFILES
- 4.1 Acorda Therapeutics, Inc.
- 4.2 AxoGen, Inc.
- 4.3 Ceregene, Inc.
- 4.4 Genzyme Corporation
- 4.5 Geron Corporation
- 4.6 Integra LifeSciences Corporation
- 4.7 Isis Pharmaceuticals, Inc.
- 4.8 Neuralstem, Inc.
- 4.9 NeuroNova AB
- 4.10 ReNeuron Group PLC
APPENDIX: COMPANY LISTING
|
